Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Streptococcus pneumoniae capsular polysaccharide antigens are complex carbohydrate polymers that encapsulate the bacterium, serving as its primary virulence factor by inhibiting phagocytosis [4]. The 10-serotype variant specifically refers to the antigens from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, which are common causes of invasive disease globally [1]. These antigens are used in conjugate vaccines, where they are chemically linked to a carrier protein (such as Protein D from non-typeable Haemophilus influenzae) to enhance immunogenicity, particularly in infants [2]. Upon administration, the immune system recognizes these polysaccharides and generates serotype-specific antibodies that facilitate bacterial clearance via opsonophagocytosis [3]. This targeted approach effectively prevents life-threatening infections including pneumonia, meningitis, and febrile bacteremia [1].
Induction of active immunity through the production of serotype-specific opsonizing antibodies and memory B-cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcus pneumoniae capsular polysaccharide antigens (10 serotypes) (PCV10 antigens).